European responses to the corona crisis

During the Coronavirus crises, the European Science-Media Hub is collecting and publishing a regular update of the most relevant releases provided by EU institutions and other European and global actors. 🆕 Last Update : 29 March 2021

April 7, 2021 update

On 07 April 2021: the European Medicines Agency (EMA)’s safety committee has concluded its review of very rare cases of unusual blood clots with AstraZeneca vaccine. EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. EMA confirms overall benefit-risk remains positive.

March 23-25, 2021 update

On 25 March 2021: European Commission President Ursula Von der Leyen revealed that the EU has exported 77 million doses of vaccines to 33 countries since 1 December 2020. As a lead donor to COVAX, it has also contributed to exports to low and middle-income countries. She called on pharmaceutical companies to honour their contracts and match Europe’s ‘openness’ when it comes to the distribution of COVID-19 vaccines.

On 24 March 2021: the European Parliament held a Plenary debate on the Digital Green Certificate. MEPs were largely supportive of the Commission proposal although there were calls for it not to lead to a de facto need for vaccination. On the vaccine issue, practically all speakers called for the Commission to take steps to ensure that companies respect their supply commitments. Press release

On 23 March 2021: new regulations will make it easier to halt shipments of EU-made COVID vaccines leaving the EU. The Commission aims to tighten export controls of COVID-19 vaccines, as supply difficulties continue to hamper vaccination efforts.

March 15-18, 2021 update

On 18 March 2021: after concluding a preliminary review of a signal of blood clots in people vaccinated with AstraZeneca, EMA continues to support the AstraZeneca vaccine. EMA confirmed that the benefits of the vaccine outweigh the risk of side effects.
Out of 20 million people who had been vaccinated with AstraZeneca, EMA found only 7 cases of blood clots in multiple blood vessels and 18 cases of CVST (clots in the vessels draining blood from the brain). According to EMA, a causal link with the vaccine is not proven, but is possible and deserves further analysis. The product information of the vaccine will be updated.

On 17 March 2021: the European Commission proposes a Digital Green Certificate to facilitate safe free movement inside the EU during the COVID-19 pandemic. The Digital Green Certificate will be a proof that a person has been vaccinated against COVID-19, received a negative test result or recovered from COVID-19. It will be available, free of charge, in digital or paper format. It will include a QR code to ensure security and authenticity of the certificate.

On 16 March 2021: the eHealth Network (consisting of all EU member states and Norway) published guidelines for EU countries to be used in order to create interoperable proofs of vaccination that are reliable and verifiable and can be presented by its holder upon request.

These guidelines are the result of the discussions and reflections stemming from the eHealth Network and its subgroups on Semantics and Technical interoperability so far, as well as first consultations with Health Security Committee, EMA, ECDC and WHO.

On 15 March 2021: while EMA is investigating a number of events of blood clots in people who had received the AstraZeneca vaccine, several EU countries have temporarily paused vaccination with the vaccine. This is a precaution taken in the light of their national situation.

At this time, EMA remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects.

On 15 March 2021: the European Parliament published ‘Covid-19 variants: state of play and impact on vaccination in the EU‘.

As part of Parliament’s continued close monitoring of the EU’s vaccination strategy, members of the environment and public health committee heard from representatives from the European Centre for Disease Prevention and Control, the European Medicines Agency and the World Health Organization on the efficacy of vaccines against mutations of the Covid-19 virus.

March 1-4, 2021 update

On 4 March 2021: the European Medicines Agency (EMA) announced that its human medicines committee (CHMP) had started a rolling review of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology. The EU applicant for this medicine is R-Pharm Germany GmbH.
On 3 March 2021: the European Space Agency and the European Commission announced the launch of a new series of monthly challenges asking for innovative solutions on how satellite data can be used to help better understand the effects of COVID-19 on society, economy and the environment. Each challenge, published at the beginning of each month, will be based on a specific interdisciplinary theme focusing on how different components of the environment interact with pandemic-driven changes around the world.
On 2 March 2021: the European Commission announced that Ghana and Côte d’Ivoire were the first countries to receive and start administering COVID-19 vaccines provided by the Gavi COVAX Advanced Market Commitment (AMC).
On 2 March 2021: the European Medicines Agency (EMA) and Health Canada announced the publication of clinical data used to support their authorisations of the Moderna COVID-19 vaccine.

On March 1 2021: EU Ministers of Health held an informal video conference chaired by Marta Temido, Minister for Health of Portugal, which focused on the appearance of new variants of COVID-19 and the importance of new approaches to testing and vaccination processes in the EU countries. The majority of the Member States highlighted the importance of a coordinated approach to the pandemic as one of the aspects essential to the success of the response. Remarks by Health Commissioner Stella Kyriakides can be accessed here .

Leave a Reply